Ranbaxy Receives Rare Distinction at ILC Power Brand 2013

Ranbaxy Receives Rare Distinction at  ILC Power Brand 2013

Ranbaxy CEO Arun Sawhney Is Declared the CEO of the Year, Volini,Revital & Chericof Cough Syrup Voted Power Brands at 4^th Annual India Leadership Conclave & Indian Affairs Business Leadership Awards 2013

Mumbai, Maharashtra, India, Saturday, 29^th June 2013: Indian Pharma Major Ranbaxy, Country’s biggest & largest drug maker Ranbaxy shined at the historic platform of Indian Affairs Business Leadership Awards 2013 as it bagged the coveted CEO of the Year to its dynamic & aggressive CEO & MD, Mr Arun Sawhney under open public voting that ran for 60 days in 17 states & 3 countries by the Indian Affairs Juries, independent experts declared Ranbaxy as Winner at the closing ceremony of the glittering Award Night. Organized by Network 7 Media Group’s Indian Affairs in association with Breakfastnewstv, Pharmaleaders, Ranbaxy Global Consumer Healthcare (RGCH) which has been at the forefront of maintaining leadership position in the OTC market has been voted by the general public in the open nomination category for its successful brands Revital,Volini & Cheridof syrup. Ranbaxy which has been in the news post Daiichi-Sankyo takeover from Singh Brothers has expanded its base under the dynamic leadership of its CEO Arun Sawhney.

Ranbaxy Global Consumer Healthcare (RGCH) received two coveted & prestigious Awards at the power-packed gatherings with Chericof receiving the Emerging Brand of the Year & Volini & Revital as Brands of the Decade. The honor  came after the sixty days of voting by the public conducted by the Research team of Indian Affairs, It may be recalled that Ranbaxy is India’s largest pharmaceutical company and has a product portfolio that covers all major therapy areas, including Anti-infectives, Nutritional, Gastrointestinal, Pain management, Cardiovascular & Diabetes, Dermatology, Urology and Central Nervous System (CNS). Ranbaxy has also have a strong presence in the Novel Drug Delivery System (NDDS) segment. Incorporated in the year 1961 with more than 200 Molecules with some Leading Molecules such as Sporidex (Cephalexin), Cifran (Ciprofloxacin), Mox (Amoxycillin), Zanocin (Ofloxacin), Storvas (Atorvastatin), Oframax (Ceftriaxone), Cepodem (Cefpodoxime), Moxclav (Amoxicillin+Clavulanic Acid), Cilanem (Imipenem+Cilastatin), Volini (Diclofenac combination), Silverex (Silver Sulphadiazine), Cepodem (Cefpodoxime), Volini (Diclofenac), Revital (Nutritional)

Receiving the prestigious honors at the Conclave, Mr. Brijesh Kapil, Vice-President of Ranbaxy Global Consumer Healthcare (RGCH) said “Ranbaxy Global Consumer Healthcare (RGCH) which is a separate business division through which Ranbaxy develop and market Over-the-Counter (OTC) products in more than 20 countries across Asia, Africa, the Middle East and Europe. This division is one of Ranbaxy fastest growing and offers 15 products, including some top-selling brands that have leadership status in their respective segments. Some of Ranbaxy key OTC brands are Revital, Volini, Faringosept, Aspenter and Chericof. RGCH commenced its operations in 2002 with the launch of Pepfiz, Gesdyp and Garlic Pearls in the Indian market. The portfolio was strengthened with the addition of Revital. In 2005, Chericof was added to the offering and, in 2007, Volini, a topical analgesic brand, was introduced. Today, Revital, Ranbaxy flagship brand in the OTC segment, is India’s largest selling Vitamins & Minerals Supplement. It is also among the Top 5 OTC brands of India. Volini is among the fastest growing pain relievers available in India. It is also counted amongst the Top 10 brands in the Indian pharmaceutical market. Some of Ranbaxy other key OTC brands are Revital Woman, Volini Activ and Revitalite. At RGCH, Ranbaxy strive relentlessly to enhance the Ranbaxyll-being of consumers by providing innovative healthcare solutions. Ranbaxy follow the model of staying in constant touch with the market through research and responding to its needs through appropriate products. The division has an aggressive sales and distribution strategy that involves penetrating Class II towns directly and smaller towns through the ‘hub and spoke’ model. Ranbaxy pursue a differentiated sales and distribution strategy of engaging FMCG/OTC distributors for Ranbaxy OTC products. The distribution infrastructure continues to grow, with about 1000+ distributors and sales representatives covering outlets that account for more than 90% of category volumes for all Ranbaxy major OTC brands”.

Addressing the audience which comprised of more than 300 iconic leaders at the India Leadership Conclave platform, after receiving the CEO of The Year Award trophy bestowed to Mr Arun Sawhney, on behalf of its CEO & MD , Mr. Arun Sawhney, Brijesh said “Mr. Sawhney is an industry veteran, with over three decades of international experience in the Chemical and Pharmaceutical arena. He has held senior functional and management positions in global pharmaceutical companies like Max-Gb, Hindustan Ciba-Geigy, Bayer India Limited and Dr. Reddy’s Laboratories Limited & Mr. Sawhney is one of the founder members of the Pharmaceuticals Export Promotion Council of India (Pharmexcil) and is currently a member of the Advisory Board of the United States Pharmacopeia (USP) in India. He is also the Chairman of the Confederation of Indian Industry (CII)’s National Committee on Pharmaceuticals and a Member of the India-Malaysia CEO Forum, the India-South Africa CEO Forum and the India Africa Business Council constituted by the Government of India. Mr. Sawhney has been Chairman of the Pharmaceutical Committee of the Federation of Indian Chambers of Commerce and Industry (FICCI). Mr Sawhney has been instrumental in the success story of Ranbaxy”.

Mr Kewal Handa, Former Pfizer Chief, Dr Mukesh Batra, CMD, Dr Batra’s & Mr Satya Brahma, Chairman & Editor-In-Chief of Indian Affairs Ranbaxyre present to give away the coveted honors to the Ranbaxy.